×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Articles

Kristie L. Kahl
A recent survey of physicians revealed that 17 percent of doctors with personal experience with cancer were more likely than those without to act against established guidelines to recommend that low-risk women receive ovarian cancer screening.
Jason M. Broderick
The FDA has approved Imbruvica (ibrutinib) for use in combination with Rituxan (rituximab) as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia.
 
Jessica Skarzynski
Broad-based genomic sequencing, while useful in identifying tumor mutations in patients with non-small cell lung cancer (NSCLC), may not improve survival outcomes when compared to routine genomic testing.
Brielle Urciuoli
Senator and former presidential candidate John McCain died of glioblastoma on Aug. 25. He was 81 years old.
Brielle Urciuoli
The senator's family announced that he will no longer be undergoing treatment for glioblastoma.
Kristie L. Kahl
In a recent study, researchers from the American Cancer Society found that patients who reported higher satisfaction with their physician’s communication also had better health outcomes at lower costs.
Brielle Urciuoli
"One of the big challenges in lymphoma is that many immune cells are present right in the tumor, but somehow those immune cells are not actually killing the tumor cells," explained Stephen M. Ansell, M.D., Ph.D.
Brielle Urciuoli
According to a recent study conducted at the University of Alabama at Birmingham Schools of Public Health and Medicine, disparities among patients who receive instructions for this follow-up care still exist.
Kristie L. Kahl
CURE spoke with Matthew Mossanen, M.D., from the Division of Urology at Brigham and Women’s Hospital, about what Bacillus Calmette-Guérin (BCG) is and what patients should know about this treatment option.
Jason M. Broderick
The FDA has granted a priority review to a supplemental biologics license application (sBLA) for Empliciti (elotuzumab) for use in combination with Pomalyst (pomalidomide) and low-dose dexamethasone (EPd) for the treatment of patients with relapsed/refractory multiple myeloma following two or more prior therapies, including Revlimid (lenalidomide) and a proteasome inhibitor (PI).
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable